Acusphere Promotes Richard Walovitch, Ph.D. to Senior Vice President, Clinical Research; Demonstrated Extensive Contrast Agent and Perfusion Imaging Expertise.

WATERTOWN, Mass. -- Acusphere, Inc. (NASDAQ: ACUS) announced today that Rick Walovitch, Ph.D. has been promoted to Senior Vice President of Clinical Research, effective immediately. Dr. Walovitch has served as Vice President of Clinical Research at Acusphere since 1997.

During his tenure at Acusphere, Dr. Walovitch has directed all functions of Acusphere's clinical operations and is responsible for developing and implementing the worldwide clinical strategy for AI-700, currently in Phase 3 clinical trials. His experience includes all phases of preclinical, clinical, nominating and NDA (New Drug Application) processes.

"Rick has demonstrated that he can effectively recruit and manage clinical sites on a global basis including all personnel, operating procedure and data management requirements. Throughout Acusphere's history, the Phase 1 and Phase 2 clinical trials designed by Rick have achieved their intended results and he has been instrumental in moving our lead product, AI-700, into and forward in Phase 3 trials," said Sherri C. Oberg, President and Chief Executive Officer of Acusphere. "His experience and pharmacology expertise have been, and will continue to be, enormously valuable to the company."

Dr. Walovitch has nearly 30 years of experience in preclinical and clinical research and holds a B.S. in Biology and a Ph.D. in Pharmacology from the University of Illinois.

About Acusphere, Inc.

Acusphere (NASDAQ:ACUS) is a specialty pharmaceutical company that develops new drugs and improved formulations of existing drugs using its proprietary microparticle technology. Acusphere's three initial product candidates are designed to address large unmet clinical needs within cardiology, oncology and asthma. These product candidates were created using proprietary technology that enables Acusphere to control the porosity and size of nanoparticles and microparticles in a versatile manner that allows particles to be customized to address the delivery needs of a variety of drugs. Acusphere's lead product candidate, AI-700, is a cardiovascular drug in Phase 3 clinical development. AI-700 is designed to enable ultrasound to compete more effectively with nuclear stress testing, the leading procedure for detecting coronary heart disease. An estimated 9.5 million procedures are done each year in the U.S. to detect coronary heart disease, the leading cause of death in the United States. For more information about Acusphere visit the Company's web site at www.acusphere.com.

This Release contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 21E of the Securities Exchange Act of 1934. Investors are cautioned that this press release may include statements which are not strictly historical statements, including statements relating to AI-700 regarding the probability for achieving the clinical endpoints needed for regulatory approval and the nature and outcome of the results in the AI-700 clinical trials. The Company's actual results may differ materially from those anticipated in these forward-looking statements based upon a number of factors, including anticipated operating losses and existing capital obligations, uncertainties associated with research, development, testing and related regulatory approvals, including uncertainties regarding the ultimate outcome of Acusphere's Phase 3 clinical trials for AI-700 and uncertainties regarding the number of patients required to complete the Phase 3 clinical trials, uncertainties regarding the cost, timing and ultimate success of the build-out of the Company's commercial manufacturing facility, including qualifying such facility in accordance with applicable regulatory requirements, unproven markets, future capital needs and uncertainty of additional financing, competition, uncertainties associated with intellectual property, complex manufacturing, high quality requirements, lack of commercial manufacturing experience, dependence on third-party manufacturers, suppliers and collaborators, lack of sales and marketing experience, loss of key personnel, uncertainties associated with market acceptance and adequacy of reimbursement, technological change and government regulation, and other risks and challenges detailed in the Company's filings with the U.S. Securities and Exchange Commission, including the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2005. Readers are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this Release. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this Release or to reflect the occurrence of unanticipated events.